Sangamo Therapeutics, Inc. (SGMO)

$0.84

+0.01

(+1.41%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $0.81
    $0.85
    $0.84
    downward going graph

    3.33%

    Downside

    Day's Volatility :4.47%

    Upside

    1.18%

    downward going graph
  • $0.29
    $1.48
    $0.84
    downward going graph

    65.35%

    Downside

    52 Weeks Volatility :80.33%

    Upside

    43.24%

    downward going graph

Returns

PeriodSangamo Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
88.32%
3.7%
0.0%
6 Months
51.43%
8.3%
0.0%
1 Year
45.1%
17.1%
0.0%
3 Years
-90.61%
21.3%
-20.3%

Highlights

Market Capitalization
171.9M
Book Value
$0.11
Earnings Per Share (EPS)
-1.38
PEG Ratio
0.0
Wall Street Target Price
3.8
Profit Margin
0.0%
Operating Margin TTM
-9413.48%
Return On Assets TTM
-58.29%
Return On Equity TTM
-194.05%
Revenue TTM
12.3M
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
-94.8%
Gross Profit TTM
-138.6M
EBITDA
-185.0M
Diluted Eps TTM
-1.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-0.23
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Sangamo Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 352.38%

Current $0.84
Target $3.80

Company Financials

FY18Y/Y Change
Revenue
84.5M
↑ 130.95%
Net Income
-68.3M
↑ 25.23%
Net Profit Margin
-80.91%
↑ 68.32%
FY19Y/Y Change
Revenue
102.4M
↑ 21.29%
Net Income
-75.8M
↑ 10.95%
Net Profit Margin
-74.02%
↑ 6.89%
FY20Y/Y Change
Revenue
118.2M
↑ 15.39%
Net Income
-121.1M
↑ 59.75%
Net Profit Margin
-102.48%
↓ 28.46%
FY21Y/Y Change
Revenue
110.7M
↓ 6.34%
Net Income
-178.3M
↑ 47.2%
Net Profit Margin
-161.06%
↓ 58.58%
FY22Y/Y Change
Revenue
111.3M
↑ 0.54%
Net Income
-192.3M
↑ 7.84%
Net Profit Margin
-172.76%
↓ 11.7%
FY23Y/Y Change
Revenue
176.2M
↑ 58.34%
Net Income
-257.8M
↑ 34.09%
Net Profit Margin
-146.3%
↑ 26.46%
Q1 FY23Q/Q Change
Revenue
158.0M
↑ 480.08%
Net Income
21.1M
↓ 140.66%
Net Profit Margin
13.38%
↑ 204.25%
Q2 FY23Q/Q Change
Revenue
6.8M
↓ 95.67%
Net Income
-114.5M
↓ 641.84%
Net Profit Margin
-1.7K%
↓ 1688.67%
Q3 FY23Q/Q Change
Revenue
9.4M
↑ 37.5%
Net Income
-104.2M
↓ 9.03%
Net Profit Margin
-1.1K%
↑ 566.94%
Q4 FY23Q/Q Change
Revenue
2.0M
↓ 78.27%
Net Income
-60.3M
↓ 42.11%
Net Profit Margin
-3.0K%
↓ 1844.44%
Q1 FY24Q/Q Change
Revenue
481.0K
↓ 76.44%
Net Income
-49.1M
↓ 18.59%
Net Profit Margin
-10.2K%
↓ 7252.82%
Q2 FY24Q/Q Change
Revenue
356.0K
↓ 25.99%
Net Income
-36.1M
↓ 26.4%
Net Profit Margin
-10.1K%
↑ 57.3%
FY18Y/Y Change
Total Assets
590.4M
↑ 105.9%
Total Liabilities
223.9M
↑ 126.5%
FY19Y/Y Change
Total Assets
637.5M
↑ 7.98%
Total Liabilities
204.8M
↓ 8.53%
FY20Y/Y Change
Total Assets
938.6M
↑ 47.22%
Total Liabilities
441.2M
↑ 115.45%
FY21Y/Y Change
Total Assets
721.9M
↓ 23.08%
Total Liabilities
346.6M
↓ 21.44%
FY22Y/Y Change
Total Assets
562.5M
↓ 22.08%
Total Liabilities
267.6M
↓ 22.8%
FY23Y/Y Change
Total Assets
165.3M
↓ 70.61%
Total Liabilities
82.4M
↓ 69.19%
Q1 FY23Q/Q Change
Total Assets
440.6M
↓ 21.68%
Total Liabilities
105.0M
↓ 60.77%
Q2 FY23Q/Q Change
Total Assets
325.1M
↓ 26.21%
Total Liabilities
91.4M
↓ 12.89%
Q3 FY23Q/Q Change
Total Assets
219.7M
↓ 32.42%
Total Liabilities
84.8M
↓ 7.28%
Q4 FY23Q/Q Change
Total Assets
165.3M
↓ 24.75%
Total Liabilities
82.4M
↓ 2.76%
Q1 FY24Q/Q Change
Total Assets
129.0M
↓ 21.99%
Total Liabilities
72.3M
↓ 12.34%
Q2 FY24Q/Q Change
Total Assets
93.0M
↓ 27.87%
Total Liabilities
69.3M
↓ 4.07%
FY18Y/Y Change
Operating Cash Flow
37.2M
↑ 232.34%
Investing Cash Flow
-178.1M
↑ 120.14%
Financing Cash Flow
231.7M
↑ 137.67%
FY19Y/Y Change
Operating Cash Flow
-144.4M
↓ 488.68%
Investing Cash Flow
-59.8M
↓ 66.42%
Financing Cash Flow
142.0M
↓ 38.7%
FY20Y/Y Change
Operating Cash Flow
169.9M
↓ 217.64%
Investing Cash Flow
-271.6M
↑ 354.22%
Financing Cash Flow
153.1M
↑ 7.79%
FY21Y/Y Change
Operating Cash Flow
-233.3M
↓ 237.31%
Investing Cash Flow
248.2M
↓ 191.37%
Financing Cash Flow
32.9M
↓ 78.54%
FY22Y/Y Change
Operating Cash Flow
-223.6M
↓ 4.13%
Investing Cash Flow
59.3M
↓ 76.11%
Financing Cash Flow
84.7M
↑ 157.65%
Q1 FY23Q/Q Change
Operating Cash Flow
-66.3M
↑ 16.22%
Investing Cash Flow
35.7M
↓ 16.16%
Financing Cash Flow
8.0M
↓ 59.04%
Q2 FY23Q/Q Change
Operating Cash Flow
-60.7M
↓ 8.43%
Investing Cash Flow
42.5M
↑ 18.86%
Financing Cash Flow
6.5M
↓ 18.53%

Technicals Summary

Sell

Neutral

Buy

Sangamo Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc.
-2.16%
51.43%
45.1%
-90.61%
-92.29%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.48%
8.55%
19.49%
82.88%
232.15%
Novo Nordisk A/s
Novo Nordisk A/s
-13.09%
-6.28%
18.91%
138.88%
358.83%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.38%
83.19%
66.02%
36.22%
252.82%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.3%
18.97%
30.36%
165.15%
176.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc.
NA
NA
0.0
-0.5
-1.94
-0.58
NA
0.11
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc.
Buy
$171.9M
-92.29%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
232.15%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
358.83%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.8B
252.82%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
176.17%
32.84
-4.74%

Insights on Sangamo Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 9.39M → 356.0K (in $), with an average decrease of 60.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -114.50M → -36.12M (in $), with an average increase of 35.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.0% return, outperforming this stock by 20.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 36.2% return, outperforming this stock by 126.8%

Institutional Holdings

  • Wasatch Advisors LP

    9.65%

  • Armistice Capital, LLC

    6.75%

  • Vanguard Group Inc

    5.71%

  • BlackRock Inc

    2.26%

  • Renaissance Technologies Corp

    1.98%

  • Jacobs Levy Equity Management, Inc.

    1.42%

Company Information

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Organization
Sangamo Therapeutics, Inc.
Employees
405
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Industry
Health Technology

Discover More

FAQs